|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Phase II, Open-label, Prospective, Single-arm, Single-center Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients
The objective of the study is to assess the safety and efficacy of treatment with hypothyroxinemia adjunct to conventional therapies in GBM patients.
100 Clinical Results associated with Musli Thyropeutics Ltd.
0 Patents (Medical) associated with Musli Thyropeutics Ltd.
100 Deals associated with Musli Thyropeutics Ltd.
100 Translational Medicine associated with Musli Thyropeutics Ltd.